Related Experiment Video

Updated: Jun 8, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

The scientific basis for novel treatments of systemic sclerosis

Christian Beyer1, Jörg Hw Distler

  • 1Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg Universitätstrasse 27, 91054 Erlangen Germany.

F1000 Medicine Reports
|October 16, 2010
PubMed

Insights

Molecular studies reveal promising antifibrotic treatments for systemic sclerosis. Several biological therapies are now in clinical trials, offering hope for this progressive, profibrotic condition.

Area of Science:

  • Rheumatology
  • Immunology
  • Fibrosis Research

Background:

  • Systemic sclerosis is a progressive, fibrotic disease with limited treatment options.
  • Molecular studies have identified key pathways involved in fibrosis.
  • There is a need for effective antifibrotic therapies.

Purpose of the Study:

  • To review emerging antifibrotic treatment strategies for systemic sclerosis.
  • To highlight biological therapies currently in clinical trials.

Main Methods:

  • Literature review of recent molecular studies in systemic sclerosis.
  • Analysis of ongoing clinical trials for antifibrotic biologicals.

Main Results:

  • Multiple potential antifibrotic targets have been identified.
  • Several biological agents have advanced to clinical trials.

Conclusions:

  • Emerging molecular insights offer new therapeutic avenues for systemic sclerosis.
  • Biological therapies in clinical trials represent a promising frontier for managing this disease.

More Related Videos

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice08:09

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...